Sutro Biopharma downgraded by Citizens JMP
$STRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citizens JMP downgraded Sutro Biopharma from Mkt Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $2.00 | Neutral → Overweight | Piper Sandler |
| 3/17/2025 | Buy → Neutral | H.C. Wainwright | |
| 3/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 3/14/2025 | $8.00 → $2.00 | Outperform → Neutral | Wedbush |
| 3/14/2025 | $11.00 → $1.00 | Buy → Underperform | BofA Securities |
| 5/8/2024 | $12.00 | Buy | BofA Securities |
| 11/9/2023 | $12.00 | Buy | Deutsche Bank |
| 10/6/2023 | $10.00 | Outperform | Oppenheimer |
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. "We are delighted to welcome Greg to Sutro's executive leadership team," said Jane Chung, Chief Executive Officer of Sutro. "Greg brings a strong track record of driving financial discipline, o
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within Astellas iADC collaboration, triggering $7.5 million milestone payment to Sutro - - Cash, cash equivalents and marketable securities as of March 31, 2025 of $249.0 million, with cas
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company's website at www.sutrobio.com. Archived replays will be available